Thirunavukkarasu, Sathish http://orcid.org/0000-0002-2016-4964
Taylor, Roy http://orcid.org/0000-0001-6273-0170
Khunti, Kamlesh
Tapp, Robyn J.
Raben, Anne http://orcid.org/0000-0001-5229-4491
Zhu, Ruixin
Kapoor, Nitin
Narayan, K M Venkat http://orcid.org/0000-0001-8621-5405
Ali, Mohammed K. http://orcid.org/0000-0001-7266-2503
Shaw, Jonathan E.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR002378)
Article History
Received: 4 November 2023
Accepted: 22 February 2024
First Online: 1 March 2024
Competing interests
: R.T. reports lecture fees from Lilly and Novartis and consultancy fees from Wilmington Healthcare and the Fast800, outside of the submitted work. K.K. was Chair of the National Institute for Health and Care Excellence (NICE) Public Health Guidance (PH38) Type 2 diabetes: Prevention in people at high risk. A.R. has received honoraria from Nestlé, Unilever, and the International Sweeteners Association, outside of the submitted work. M.K.A. reports consulting fees from Eli Lilly, outside of the submitted work. All other authors declare no competing interests.